Varner was only able to stay on the medication using Social Security disability support. She said if she didn’t have ...

Joshua Cohen is a Boston-based writer who covers health policy. Two weeks ago, the Food and Drug Administration approved Xolair (omalizumab) for immunoglobulin E-mediated food allergy in certain ...

Xolair (omalizumab) generated revenues of more ... which is available in markets in the US and EU as a subcutaneous injection lasting a few minutes, instead of a lengthy infusion.

The approved dose is 300 mg by subcutaneous injection every four weeks. "The EU approval of Xolair in CSU is truly exciting for patients with this chronic and debilitating skin disease," said ...

Omalizumab has been shown to improve participants ... The drug is delivered as an injection every two to four weeks and targets a specific antibody called IgE. IgE - like other human antibodies ...

Omalizumab is generally well tolerated in adults and children with allergic asthma. Adverse events most commonly observed are injection-site reaction, viral infection, upper-respiratory-tract ...

The key is a drug originally designed to treat asthma patients. "The way that omalizumab, brand name Xolair, works is that it binds to your allergy cells, and it takes it out of circulation ...